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Abstract
Pharmacokinetic and Pharmacodynamic Modeling of Erythropoiesis Stimulating
Agents in Rats
Wendi Chen
Leonid Hrebien, Ph.D. and Moshe Kam, Ph.D.
Erythropoiesis is a process by which red blood cells are produced in the bone mar-
row. Disruption of this process can lead to anemia. Erythropoiesis stimulating agents
(ESAs), such as epoetin-α and darbepoetin-α, have been developed to treat anemia.
CNTO 530 is a novel ESA that has a longer terminal half-life than either epoetin-α
or darbepoetin-α. As these ESAs all activate erythropoietin receptor (EPO-R), we
hypothesize that any differences in the pharmacologic activity are solely dependent on
their pharmacokinetic properties. To test this hypothesis, we proposed a new Phar-
macokinetic/Pharmacodynamic (PK/PD) model to account for the pharmacological
response. Rats received a single subcutaneous (s.c.) dose of the ESA and reticulocyte
(RET) counts, red blood cell (RBC) counts and hemoglobin (HGB) levels were mea-
sured for up to 72 days (1728 hours) post-dosing. Various dosage levels were studied
for each drug. A new indirect response model with multiple regulatory effects was used
to characterize the PD responses and a linear two-compartmental model was used to
characterize the PK responses. All three agents caused a dose responsive increase in
RET, RBC and HGB. Compared to epoetin-α and darbepoetin-α, CNTO 530 caused
a longer-lived increase in these parameters. A single PK/PD model could represent
all three agents. However, when comparing among the erythropoietic responses to
xiii
doses that increased RBC, the coefficients of the model indicate that despite having
a lower potency, CNTO 530 caused a more rapid mobilization of RET. The results of
the PK/PD modeling suggest that CNTO 530 stimulates erythropoiesis in a similar
fashion to epoetin-α and darbepoetin-α and that the PK properties of an ESA are
the most important factor in determining efficacy. In addition, dose threshold is an
important factor we need to consider in designing the PK/PD model. Understanding
dose threshold of a drug aids in determining appropriate dose levels and, therefore,
helps diminish side effects of the compound and reduces treatment costs. Many stud-
ies have focused on non-quantitative analysis of drug dose threshold, which can be
biased by various factors. Aiming for quantitative analysis of this parameter, we
proposed two statistical methods to determine dose threshold of a drug and applied
them to CNTO 530.

1Chapter 1: Biological Background
1.1 Physiology of Erythropoiesis
Erythropoiesis is a complicated process by which red blood cells are produced from
bone marrow and then mature in the circulation. In this process, a hematopoi-
etic stem cell (HSC) undergoes a series of differentiations (Koury et al., 2002). As
seen in Figure 1.1, inside the bone marrow, a HSC firstly grows to a burst form-
ing unit-erythroid (BFU-E). Then the BFU-E undergoes some changes to become a
colony forming unit-erythroid (CFU-E). This CFU-E becomes morphologically iden-
tifiable erythroid precursor with cytoplasm: proerythroblast (Pro-EB), basophilic-
erythroblast (Baso-EB), polychromatophilic-erythroblast (Poly-EB) and orthochromic-
erythroblast (Ortho-EB). Later, the cell develops into an immature red blood cell
called a reticulocyte (RET) in the bone marrow and is then released into the blood
stream. Ultimately it becomes a mature red blood cell (RBCM). After the Poly-EB
stage, erythroid cells undergo highly specialized maturation, and their nuclei shrink
with condensed chromatin. RBCM are biconcave disks with no nucleus and are com-
posed mostly of hemoglobin.
There are several factors regulating erythropoiesis. A major regulator of erythro-
poiesis in mammals is erythropoietin (EPO) (Krantz, 1991). EPO is a glycoprotein
hormone produced mainly by the peritubular cells in the kidneys (Wu et al., 1995). It
binds to the erythropoietin receptor (EPO-R) on the cell surface and activates several
2Figure 1.1: The relative sizes and nucleus to cytoplasm ratios of erythroid cells
at various stages of erythropoiesis (adapted from (Bugelski, 2005; Koury et al.,
2002): the color of the cytoplasm describing the relative content of ribosomes
(dark blue) and hemoglobin (red).
signal transduction pathways (Fisher, 2003; Richmond et al., 2005). CFU-E has the
highest number of EPO-R and therefore is the primary target cell in the bone mar-
row acted on by EPO (Fisher, 1997). Binding with EPO-R, EPO not only increases
the number of erythroid precursors but also accelerates the release of reticulocytes
from the bone marrow without markedly altering the cell cycle length or number of
mitotic divisions involved in the differentiation process (Spivak, 1986). Additionally,
EPO may decrease the rate at which EPO-dependent progenitor cells undergo pro-
3grammed cell death (apoptosis) (Fisher, 1997). Blood oxygenation can also affect
the erythropoiesis process (Koury et al., 2002). It is a feed-back mechanism: oxygen
tension in blood regulates erythropoiesis process and hemoglobin is responsible for
oxygen delivery, changing oxygen level.
1.2 Erythropoiesis Stimulating Agents
The malfunction or lack of EPO can severely disrupt the production of red blood cells,
which can potentially lead to anemia. Erythropoiesis Stimulating Agents (ESAs) are
agents, structurally and biologically, similar to endogenous EPO and were developed
to help treat anemia. In our research, we studied three ESAs: epoetin-α, darbepoetin-
α, and CNTO 530. Epoetin-α and darbepoetin-α have been widely used with patients
whose normal erythropoietic processes have been undermined due to chronic renal
failure, certain types of cancer or AIDS (Bunn, 2007; Jelkmann, 2002). CNTO 530 is
a novel erythropoiesis stimulating agonist newly developed by Centocor Ortho Biotech
Products, L.P..
1.2.1 Two commercially available ESAs
Epoetin-α, sometimes referred to as recombinant human erythropoietin (rHuEPO),
is an exogenous EPO manufactured by recombinant DNA technology. It contains the
identical amino acid sequence and has the same biological effects as endogenous EPO
(Egrie et al., 1986). It is marketed by Centocor Ortho Biotech Products, L.P. under
the trade name Procrit R© and by Amgen Inc. under the trade name Epogen R©. Both
of them are man-made injectable drugs for treating anemia.
4Darbepoetin-α is a hyperglycosylated epoetin-α analogue, containing five N-linked
carbohydrate chains, two more than epoetin-α (Egrie and Browne, 2001). In the study
conducted by Egrie and Browne (2001), sialic acid-containing carbohydrates of EPO
are directly related to its circulating half-life, and in vivo biological activity, but
inversely related to its receptor-binding affinity. Due to its additional carbohydrate
chains, darbepoetin-α has approximately a 4-fold lower EPO-R binding activity, a 3-
fold longer circulating half-life and greater in vivo biological activity than epoetin-α
(Egrie et al., 2003). It is marketed by Amgen Inc. under the trade name Aranesp R©.
Similar to epoetin-α, darbepoetin-α is produced using recombinant DNA technology.
1.2.2 One newly developed ESA
CNTO 530 is a newly designed ESA which is different from epoetin-α and darbepoetin-
α since it has no sequence homology with EPO. It is an antibody Fc domain fusion
protein containing two erythropoietin mimetic peptide-1 (EMP1) sequences as a phar-
macophore (Bugelski et al., 2008). It mediates different physiological effects by bind-
ing to various cell receptors. EMP1 is a non-erythropoietin derived EPO-R agonist.
It binds to EPO-R and mediates the same signal transduction systems to produce
similar effects as EPO. Fusion proteins are molecular constructs in which two genes
are joined together and express as a single gene product. Since CNTO 530 is an
antibody fusion protein where two EMP1 sequences are linked to the Fc domain, it
can bind to EPO-R and express EPO-liked bioactivity while the Fc domain provides
for extended pharmacokinetic properties.
51.2.3 Different biological properties
ESAs can have very different chemical and biological properties as has been shown
in previous studies (Bugelski et al., 2007; Bunn, 2007; Egrie et al., 2003). Epoetin-
α has a relatively short terminal half-life of 4-8 hours in humans and needs to be
administrated 2-3 times a week (Faulds and Sorkin, 1989; Jelkmann, 2002). In addi-
tion, some patients have developed anti-EPO antibodies due to immunogenicity which
can reduce the benefit of taking epoetin-α (Bunn, 2007). Compared with epoetin-α,
darbepoetin-α has a longer half-life of 25.3 to 48.8 hours in humans (Macdougall,
2001), and greater in vivo biological activity, which allows for less frequent admin-
istration (Bunn, 2007). Although it has not been tested in humans, CNTO 530 has
shown a terminal half-life of 40 hours in mice (Bugelski et al., 2008; Sathyanarayana
et al., 2009) and 72 hours in rats after a single s.c. administration (Martin et al.,
2010). In comparison, the half-lives for epoetin-α and darbepoetin-α in rats after a
single s.c. administration are 7.8 hours (Woo et al., 2006) and 15 hours (Yoshioka
et al., 2007), respectively.
6Chapter 2: Background on Pharmacokinetic and
Pharmacodynamic Analysis
Pharmacokinetics explores what the body does to the drug, i.e., the movement of a
drug into, through, and out of the body. Pharmacodynamics explores what a drug
does to the body, i.e., the physiological effects of drugs on the body and the mech-
anisms of drug action. Pharmacodynamics (PD) combined with pharmacokinetics
(PK) helps explain the relationship between the drug dose and response (see Figure
2.1). Both are very complex biological processes and mathematical models have been
developed to explore the biological mechanisms of drugs.
Figure 2.1: Relationship between pharmacokinetics and pharmacodynamics.
Combined PK/PD studies focus on these two important subjects of pharmacol-
ogy and build connections between them (Derendorf and Meibohm, 1999). They link
the time course of drug concentration as assessed by pharmacokinetics to the time-
invariant relationship between the concentration at the application site and the effect
intensity as characterized by pharmacodynamics (see Figure 2.2). Thus, PK/PD
models allow us to describe the time course of the effect intensity resulting from the
7administration of a certain dosage regimen. Levy (1964) did the pioneering work to
link the pharmacokinetics of a drug with the subsequent in vivo pharmacological re-
sponse. Widespread use of PK/PD concepts started in early 1980 when the temporal
dissociation between the effect intensity and the drug concentration could be solved
by the effect-compartment model developed by Sheiner and coworkers (Holford and
Sheiner, 1981a,b, 1982; Sheiner et al., 1979).
Figure 2.2: PK/PD modeling as combination of two pharmacological processes:
pharmacokinetics describing concentration-time courses of drugs and pharmaco-
dynamics describing effect-concentration relationships of drugs. Source: (Deren-
dorf and Meibohm, 1999)
This thesis studied biological properties of three ESAs, epoetin-α, darbepoetin-α
and CNTO 530. It is important to compare pharmacokinetics and pharmacody-
namics to determine differences between biological properties of these ESAs. The
differences may help doctors better choose the most appropriate treatment option for
anemic patients. However, in practice it can be difficult to make a meaningful com-
parison between two sets of parameters obtained from two different PK/PD models.
8It is known that epoetin-α, darbepoetin-α, and CNTO 530 have similar molecular
mechanisms which initiate several signal transduction pathways by binding EPO-R
to stimulate red blood cell production (Bugelski et al., 2008; Egrie and Browne, 2001;
Egrie et al., 1986). Due to these similarities it may be possible to use a single PK/PD
model structure to describe these three ESAs. If such a model can be found, a direct
mathematical comparison of PK/PD parameters can be made across all three ESAs.
However, few attempts have been made to develop a single PK/PD model for multiple
ESAs.
2.1 Pharmacokinetic Analysis
Generally, as shown in Figure 2.3, there are four processes studied by pharmacoki-
netics (Gibaldi and Perrier, 1982; Groulx, 2006):
• Absorption is the process by which a drug infiltrates from an administration
site into the bloodstream of the body. A drug can be administered through
various routes, such as intramuscular (i.m.), intravenous (i.v.), subcutaneous
(s.c.), oral, etc.
• Distribution is the process by which a drug is transported through body fluids
from the bloodstream to the tissues of the body. It is assumed that the drug is
uniformly distributed throughout the body.
• Metabolism is the process by which a drug is chemically inactivated in prepara-
tion for elimination from the body. Some drugs are metabolized quickly, while
others can take longer before they are eliminated.
9• Excretion is the process by which a drug is eliminated from the body. Immedi-
ately after administration of a drug , the body begins to eliminate via hepatic
metabolism, renal excretion, or both.
Figure 2.3: Four processes involved in pharmacokinetics: absorption, distribu-
tion, metabolism and excretion (ADME).
In order to provide safe and effective dose to patients, it is essential to understand
how a drug interacts with the body at different dose level. However, unless a drug has
the property of dose proportionality, obtaining a complete pharmacokinetic profile
for all possible doses of a drug is difficult. Dose proportionality implies that the
rates of absorption, distribution, metabolism, and elimination remain constant over a
certain dose range (Gibaldi and Perrier, 1982). Many drugs have the property in their
therapeutical range, which makes it easier to study their PK effects (Gabrielsson and
Weiner, 2007).
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Pharmacokinetic analysis can be conducted by either non-compartmental analysis
or compartmental analysis (Gibaldi and Perrier, 1982). Non-compartmental analysis
uses numeric methods to estimate the exposure to a drug (Yoshioka et al., 2007).
The advantage of non-compartmental analysis is that it requires fewer assumptions
than those which are necessary with compartmental analysis. The disadvantage of
non-compartmental analysis is that it highly depends on the blood/plasma sampling
schedule. Compartmental analysis uses kinetic models to describe and predict the
concentration-time curve. The advantage of compartmental analysis is its ability to
predict the concentration at any time. In addition, with the property of dose propor-
tionality, PK compartmental models of a drug could help predict the concentration
versus time profiles at other dose levels. The disadvantage of compartmental analysis
is the difficulty in developing and validating such models.
2.1.1 Non-compartmental pharmacokinetic analysis
Many studies have used non-compartmental pharmacokinetic analysis (Bugelski et al.,
2008; Cheung et al., 1998; Yoshioka et al., 2007). There are eight important non-
compartmental model parameters:
• AUC: the area under the concentration-time curve. This term can be used to
calculate overall clearance values for a drug. In addition, AUC is frequently
used to compare drug exposures achieved with different drug doses.
• Vd: volume of distribution. It is the theoretical volume of fluid into which the
total amount of drug administered would have to be uniformly distributed to
produce the drug concentration in plasma. It is an important indicator of the
11
extent of drug distribution into fluids and tissues. Initial drug concentration is
calculated as drug dose divided by Vd. A large volume of distribution indicates
that the drug distributes extensively into body tissues and fluids. Conversely, a
small volume of distribution indicates limited drug distribution (DiPiro et al.,
2005).
• F : Bioavailability, the fraction of drug that is absorbed. It is used to de-
scribe how much drug reaches the circulation system after administration. The
bioavailability of an i.v. drug dose is assumed to be 100%. In the case of s.c.
and oral administration, F is calculated as the ratio of drug concentration after
giving the drug, compared with the same dose given intravenously.
• t1/2: terminal half-life. It is defined as the time required for the concentration of
a drug to decrease by 50% of the current concentration in the final elimination
phase. If a drug follows first-order elimination, then it would take about 5-6
half-lives for the drug to be completely removed from the body.
• λz: terminal elimination rate constant. It is defined as the exponential rate at
which drugs are removed from the body in the final elimination phase. There
is a relationship between λz and t1/2:
t1/2 =
ln(Cdrug)− ln(0.5Cdrug)
λz
=
ln 2
λz
where Cdrug is the drug concentration in the plasma or serum.
12
• CL: the volume of plasma from which the drug is completed removed per
unit time. CL/F , apparent clearance, is used in the cases of s.c. and oral
administration. CL or CL/F can be calculated using formula Dose/AUC.
• Cmax and Tmax: after a drug is administered at time 0, its concentration will
reach a peak level, Cmax, at time Tmax.
2.1.2 Compartmental pharmacokinetic analysis
Compartmental models are categorized by the number of compartments required
to describe the drug’s behavior in the body. There are one-compartment, two-
compartment, and multi-compartment models. They can be mathematically ex-
pressed using linear differential equations or non-linear differential equations (Sheiner,
1984, 1985, 1986). The compartments do not necessarily represent a specific tissue or
fluid but may represent a group of similar tissues or fluids. Because of dose propor-
tionality, these models can be used to predict concentration versus time profiles of a
drug in the body in the therapeutical range.
For one-compartmental models (Dayneka et al., 1993; Krzyzanski and Jusko,
1998), the body is assumed to be a single compartment. As shown in Figures 2.4
and 2.5, the model structure for i.v. dosing is slightly different from the one for s.c.
dosing. For both of them, C(t) is the concentration of drug in the plasma at time
t, and Kel is a first order elimination rate. For s.c. dosing, the model structure has
two additional items: Input(t) is the concentration of drug at the s.c. injection site
at time t and Ka is a first order absorption rate.
The following differential equation describes the one-compartmental PK model for
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Figure 2.4: A general one-compartmental PK model for i.v. dosing.
i.v. dose in Figure 2.4:
dC(t)
dt
= −Kel × C(t)
Initially, C(0) = Dose/Vd. There are two model parameters: Kel and Vd (volume
of distribution).
Figure 2.5: A general one-compartmental PK model for s.c. dosing.
The following differential equations describe the one-compartmental PK model for
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s.c. dose in Figure 2.5:
dC(t)
dt
= Ka × Input(t)−Kel × C(t)
dInput(t)
dt
= −Ka × Input(t)
Initially, C(0) = 0 and Input(0) = Dose× F/Vd. There are three model parame-
ters: Kel, Vd, and Ka.
For basic two-compartment models (Agoram et al., 2006; McLennan et al., 2006),
the central compartment includes the blood and well perfused organs, such as the
heart, lungs, liver and kidneys. The peripheral compartment includes poorly perfused
tissues and organs, such as the fat tissue, muscle tissue, and cerebrospinal fluid.
Similar to one-compartmental PK models, the two-compartmental PK model for s.c.
dosing has one more variable (Input(t)) and one more rate (Ka) than the one for i.v.
dosing (see Figure 2.6 and 2.7)
Figure 2.6: A general two-compartmental PK model for i.v. dosing.
The following differential equations describe the two-compartmentl PK model for
15
i.v. dose in Figure 2.6:
dCdrug(t)
dt
= −(Kel +KCP )× Cdrug(t) +KPC × CP (t)
dCP (t)
dt
= KCP × Cdrug(t)−KPC × CP (t)
where Cdrug(t) and CP (t) are the concentration of drug in the central (blood and well
perfused organs) and peripheral (poorly perfused tissues) compartments at time t,
KCP and KPC are two inter-compartment exchange rates, and VC is the volume of
distribution in the central compartment. Initially, Cdrug(0) = Dose/VC and CP = 0.
There are four model parameters: Kel, VC , KCP , and KPC .
Figure 2.7: A general two-compartmental PK model for s.c. dosing.
The following differential equations describe the two-compartmental PK model
for s.c. dosing in Figure 2.7:
dCdrug(t)
dt
= Ka × Input(t)− (Kel +KCP )× Cdrug(t) +KPC × CP (t)
dCP (t)
dt
= KCP × Cdrug(t)−KPC × CP (t)
dInput(t)
dt
= −Ka × Input(t)
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Initially, Cdrug(0) = 0, CP (0) = 0 and Input(0) = Dose × F/VC . There are five
model parameters: Kel, VC , KCP , KPC , and Ka.
Basic compartmental models can be changed to non-linear models by introducing
complicated absorption or excretion processes. For example, a complicated absorption
process may consist of dual absorption rates which combine a zero-order rate and a
first-order rate (Cheung et al., 2004; Ramakrishnan et al., 2003; Woo et al., 2006).
A complicated excretion process may involve Michaelis-Menten elimination (Cheung
et al., 2004) only, or both a first-order elimination and a Michaelis-Menten elimination
(Kato et al., 1997, 2001).
We used a one-compartment PK model to explain Michaelis-Menten elimination
(see Figure 2.8).
Figure 2.8: A one-compartmental PK model for i.v. dosing with Michaelis-
Menten elimination.
The following differential equation describes the nonlinear PK model in Figure
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2.8:
dC(t)
dt
= −Vmax × C(t)
Km + C(t)
where Vmax is the maximum elimination rate, and Km is the plasma drug concen-
tration at which the elimination rate reaches 50% Vmax. The rate of drug elimi-
nation (Vmax × C(t)/(Km + C(t))) changes as a function of drug concentration as
demonstrated in Figure 2.9. At high concentrations (C(t) >> Km), the plasma drug
concentrations decline at zero-order rate equal to Vmax. At very low concentrations
(C(t) << Km), the plasma drug concentrations decline at first-order rate Vmax/Km.
At intermediate concentrations, the plasma drug concentrations decline at a variable
rate as function of the varying plasma drug concentrations themselves.
Figure 2.9: The saturation curve of Michaelis-Menten elimination.
Most drugs in the therapeutic range are at the bottom of the Michaelis-Menten
curve and obey linear pharmacokinetics and making their this is why their plasma
concentration versus time curves exponential (Mehvar, 2001).
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2.2 Pharmacodynamic Analysis
The field of pharmacodynamic modeling has gained many advances recently because
of the development of basic and extended mechanism-based models (Mager et al.,
2003). We will focus on four classes of PD modeling approaches to illustrate their
challenges and complexities, but also opportunities to characterize the pharmacody-
namics of drugs (Crommelin et al., 2008; Derendorf and Meibohm, 1999).
• Direct response PD models;
• Indirect response PD models;
• Cell lifespan PD models;
• Ad-hoc response PD models.
2.2.1 Direct response PD models
For the direct response PD models, it is assumed that the observed effect is determined
by the effect site concentrations without time lag. In this case, maximum effects are
assumed to occur simultaneously with maximum effect site concentrations of the drug.
(Derendorf and Meibohm, 1999).
The classical direct response PD model is the sigmoid Emax model (Mager et al.,
2003) as demonstrated in Figure 2.10:
Ef(t) =
Emax × C(t)n
ECn50 + C(t)
n
where Ef(t) is the variable of pharmacological effect, Emax is the maximum achievable
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Figure 2.10: Diagram of a typical direct response PD model. It is also a sigmoid
Emax model (adapted from (Crommelin et al., 2008)).
effect, EC50 is the drug concentration that produces half of the maximum effect and n
is the shape factor that allows for an improved fit of the relationship to the observed
data. In other words, Emax represents the efficacy of the drug in the system. EC50
helps characterize the potency of the drug in the system, i.e., the sensitivity of the
organ or tissue to the drug (Derendorf and Meibohm, 1999).
2.2.2 Indirect response PD models
There often is temporal dissociation between the time course of drug concentration
and the drug effect (Dayneka et al., 1993). Such concentration-effect relationships of
many drugs could be characterized by an indirect response model. In this model, max-
imum plasma concentrations will occur before maximum effects of the drug (Crom-
melin et al., 2008). Moreover, the effect intensity will increase despite decreasing
plasma concentrations and may continue beyond the time when drug concentrations
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in plasma are no longer detectable.
Early in 1993, Dayneka et al. (1993) proposed four basic models for characterizing
indirect PD responses after drug administration which have been widely used in
studying the pharmacodynamics of numerous drugs. In each variant, the synthesis
or degradation process of the response is either stimulated or inhibited as a function
of the drug concentration at the effect site. Schematics of the four basic indirect
response models are shown in Figure 2.11. Their corresponding differential equations
are given as follows:
(a)
dR(t)
dt
= kin × II(t)− kout ×R(t)
(b)
dR(t)
dt
= kin − kout × II(t)×R(t)
(c)
dR(t)
dt
= kin × SS(t)− kout ×R(t)
(d)
dR(t)
dt
= kin − kout × SS(t)×R(t)
where R(t) is the variable for response to a drug, Kin is the zero-order constant for
production of the response and Kout is the first-order rate constant for loss of the
response.
Inhibitory function II(t) and stimulatory function SS(t) are modeled using sig-
moid model:
II(t) = 1− C(t)
IIC50 + C(t)
SS(t) = 1 +
SSmax × C(t)
SSC50 + C(t)
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(a)
(b)
(c)
(d)
Figure 2.11: Schematics of four basic indirect response PD models (Dayneka
et al., 1993) characterized by either inhibition or stimulation of the response
variable.
22
where C(t) represents plasma concentration of a drug as a function of time, IIC50
is the drug concentration which produces half of maximum inhibitory effect, SSmax
represents maximum stimulation of responses by a drug and SSC50 represents the
drug concentration for producing 50% maximum stimulation of response.
More reviews and assessments of these four basic indirect response models were
conducted by (Krzyzanski and Jusko, 1998; Sharma and Jusko, 1996). They provided
useful information as to appropriate model selection, model sensitivity to parameter
values and dose levels, and methods of obtaining initial parameter estimates from
experimental data. Furthermore, Yao et al. (2006) included empirical lower and
upper limits in the basic indirect response models to characterize drug response for
turnover systems which are maintained within a certain range.
2.2.3 Cell life span PD models
Similar to indirect response models, cell life span models are also developed based on
underlying cellular processes. They model the mechanisms of the sequential matura-
tion and lifespan-driven cell turnover of drug affected cell types and progenitor cell
populations (Crommelin et al., 2008). In particular, there are a number of protein
compounds taking effect through direct or indirect regulation of blood and/or immune
cells. For these kinds of protein compounds, cell life span models have been proven
useful to describe and predict their effects (Krzyzanski et al., 1999; Perez-Ruixo et al.,
2005). They are widely used for characterizing the dose-concentration-effect relation-
ships of hematopoietic growth factors which modify erythropoiesis, granulopoiesis,
or thrombopoiesis (Krzyzanski et al., 1999; Perez-Ruixo et al., 2005). These pro-
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cesses consist of sequential maturation of a series of cell types. The delay between
drug administration and the observed response of hematopoietic growth factors is
mainly accounted for by the fixed physiological time span for the maturation of pre-
cursor cells, i.e., change in the cell count in peripheral blood. Cell life span models
accommodate this sequential maturation of multiple types of cells by a series of tran-
sit compartments linked via first- or zero-order processes with a common constant
transfer rate.
A typical cell life span PD model is shown in Figure 2.12. This model can be
described using the following differential equation:
dR(t)
dt
= kin × SS(t)− kin × SS(t− TR) (2.1)
where, TR is the average cell life-span.
Figure 2.12: Schematic of a typical cell lifespan model (Krzyzanski et al., 1999).
2.2.4 Ad-hoc response PD models
Since the effect of many protein compounds is mediated via complex regulatory phys-
iologic processes including feedback mechanisms and/or tolerance phenomena, some
PD models have been developed to account for unique physiologic processes of some
protein drugs. On one hand, ad-hoc models may better describe individual drugs,
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and catch more details and thus are often much more sophisticated than the three
models previously discussed. On the other hand, they are not applicable as widely as
previous models due to lack of common ground.
2.3 Original Contributions
To facilitate the comparison of PK/PD model parameters for epoetin-α, darbepoetin-
α and CNTO 530, we developed a single PK/PD model for the three drugs. We
used a standard PK model (DiPiro et al., 2005) to predict the concentration profiles
of the dugs. We developed a new indirect response PD model which incorporated
the combined effect of stimulation from the drug and inhibition from hemoglobin
on the conversion of RETs to mature RBCs. The PK/PD model was then tested
using experimental data for rats and it was found that our PK/PD model fits data
collected from all three drugs over a period of at least 72 days (1728 hours), which
is longer than previous experiments. We also discovered that the PD parameters for
CNTO 530 are different from those of epoetin-α and darbepoetin-α. This suggests
that the hematological response of CNTO 530 is different from those of epoetin-α
and darbepoetin-α that does not only depend on their pharmacokinetics.
Furthermore, we developed a new statistical criterion which used our model to
predict dose threshold of a drug. In addition, we designed a normal range criterion
which can be used when control data are available. The methods were successfully
applied to the CNTO 530 data set.
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Chapter 3: Our Pharmacokinetic/Pharmacodynamic Model
Pharmacokinetic models of erythropoiesis stimulating agents have been extensively
studied in the literature (Agoram et al., 2006; Ette and Williams, 2007; Khorasheh
et al., 1999). After testing various model structures we found that a simple linear
two-compartmental PK model may be applicable on three ESAs that we studied.
However, existing PD models do not fit our data for up to 72 days. For example,
we found that existing indirect response models lacked a negative feedback and cell
lifespan models were not robust enough for analyzing drug response up to 72 days.
So we developed a new indirect response PD model that includes negative feedbacks
and is suitable for longer response periods.
3.1 Pharmacokinetic Model
Figure 3.1 shows the linear two-compartment PK model containing an absorption
rate Ka, two inter-compartment exchange rates (KCP and KPC) and an elimination
rate Kel that we chose for our data (DiPiro et al., 2005).
The following differential equations describe this model:
dCdrug(t)
dt
= Ka × Input(t)− (Kel +KCP )× Cdrug(t) +KPC × CP (t) (3.1)
dCP (t)
dt
= KCP × Cdrug(t)−KPC × CP (t) (3.2)
dInput(t)
dt
= −Ka × Input(t) (3.3)
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Figure 3.1: A two-compartmental PK model
where Cdrug(t) and CP (t) are the concentration of drug in the central (blood and well
perfused organs) and peripheral (poorly perfused tissues) compartments at time t,
and Input(t) is the concentration of drug at the s.c. injection site at time t. Initial
conditions are Cdrug(0) = 0, CP (0) = 0, and Input(0) = (Dose × F )/VC , where F
represents the bioavailability of the subcutaneously administrated drug and VC is the
volume of distribution in the central compartment.
Eq. 3.1–3.3 are linear differential equations, where the analytical solution of
Cdrug(t) can be expressed as:
Cdrug(t) =
Dose
F
(Ae−αt +Be−βt − (A+B)e−Kat) (3.4)
where
α =
(
(Kel +KCP +KPC) +
√
(Kel +KCP +KPC)2 − 4(KelKPC)
)
/2 (3.5)
β =
(
(Kel +KCP +KPC)−
√
(Kel +KCP +KPC)2 − 4(KelKPC)
)
/2 (3.6)
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A =
(KPC − α)Ka
VC(Ka − α)(β − α) (3.7)
B =
(KPC − β)Ka
VC(Ka − β)(α− β) (3.8)
(3.9)
3.2 Pharmacodynamic Model
We developed an indirect response PD model with feedback regulatory loops (Figure
3.2) to characterize the erythropoietic effects of drugs. Based on the progression of
erythropoiesis as shown in Figure 3.3. There are four compartments in our model: (1)
Early Stages, representing erythroid progenitors and erythroblasts, (2) RET, retic-
ulocyte, (3) RBCM, mature red blood cell, and (4) HGB, hemoglobin level. Unlike
previous studies (Agoram et al., 2006; Krzyzanski et al., 2005; Woo et al., 2006),
our model does not incorporate changes in the compartment of early stages or bone
marrow. Instead, a variable Kin(t) is used to model the production rate or release
of reticulocyte cells into the bloodstream. The change in Kin(t) over time is con-
trolled by an inflow rate which is proportional to drug stimulation effect S(t − Td)
and hemoglobin inhibition effect I(t− Td) and an outflow rate which is proportional
to itself (Eq. 3.10). Td is the time to mobilize reticulocytes and RBC after admin-
istration of a ESA. In the model, Kout1 and Kout2 are defined as elimination rates
of RET and RBCM states respectively. We assume that there is a combined effect
from drug concentration (E1(t)) and change of hemoglobin level (E2(t)), which affect
how reticulocytes become mature RBCs. We define E(t) = E1(t) + E2(t) to model
this effect, so that at equilibrium, E(t) equals 1, E(t) is smaller than 1 if inhibition
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Figure 3.2: A diagram showing our PD model.
dominates, and larger than 1 if stimulation dominates.
The differential equations for the two compartments are as follows:
dKin(t)
dt
= Kp × S(t− Td)× I(t− Td)−Kin(t)×Ke (3.10)
dRET (t)
dt
= Kin(t)−RET (t)×Kout1 (3.11)
dRBCM(t)
dt
= RET (t)×Kout1 × E(t)−RBCM(t)×Kout2 (3.12)
where,
S(t) = 1 +
Smax × Cdrug(t)
SC50 + Cdrug(t)
(3.13)
I(t) = 1− Imax ×∆HGB(t)
IC50 + ∆HGB(t)
(3.14)
∆HGB(t) = HGB(t)−HGBbaseline (3.15)
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Figure 3.3: A diagram of erythropoiesis.
In the above equations, an indirect mechanism of drug action is assumed with the
parameters, Smax which is the maximum stimulation of Kin(t) and SC50 which is drug
concentration required for producing 50% maximum stimulation of Kin(t) (Dayneka
et al., 1993). Because oxygen tension is a primary determinant of erythropoietic
control and hemoglobin is responsible for oxygen delivery (Greer et al., 2003; Loeﬄer
et al., 1989), a hemoglobin-driven feedback regulatory loop is used to characterize
negative erythropoietic effects (Ramakrishnan et al., 2004; Woo et al., 2006). Imax
is the maximum inhibition of Kin(t) and is assumed to be equal to 1. IC50 is the
hemoglobin change required for producing 50% maximum inhibition of Kin(t).
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Hemoglobin data were modeled with a simple linear model.
HGB(t) = RBC(t)×MCH (3.16)
where RBC(t) = RET (t) +RBCM(t) and MCH is mean corpuscular hemoglobin.
More information about the model parameters is needed to fit the model. Because
the endogenous EPO level in the control group is very low (Woo et al., 2006), we
assumed that the endogenous EPO is negligible and did not include it in the model.
The initial conditions, RET (0) and RBC(0), were taken as baseline values calculated
from the control group. RBCM(0) was calculated from RBC(0) minus RET (0).
Without drug administration, RET (t), RBC(t) and HGB(t) are assumed constant
and E(t) equals 1. Therefore, the initial values of Kin(0), KP (Kin(t) change rate),
and Kout2 (RBCM eliminate rate) can be calculated using the following equations:
Kin(0) = RET (0)×Kout1 (3.17)
KP = Kin(0)×Ke (3.18)
Kout2 = RET (0)×Kout1/RBCM(0) (3.19)
Furthermore, we assumed that Kout1 is determined by TRET the mean lifespan of
RET, i.e. Kout1 = 1/TRET .
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3.3 Derivation of Effect Function E(t)
To complete our PD model, by defining E(t) we combined some compartments and
simplified it as shown in Figure 3.4. Note that the sole purpose of this step is to
help us solve Eq. 3.10–3.16. In this model, RET and RBCM are combined into one
compartment RBC. K2out is a constant first-order elimination rate of RBC. The
variables K2in(t), S2(t − Td) and I2(t − Td) are analogous to the variables Kin(t),
S(t− Td) and I(t− Td) used in our model (Figure 3.2) and we assume that Td is the
same for both models.
Figure 3.4: The simplified PD model applied to RBC counts for solving E(t).
From Figure 3.4, we derive the following differential equations:
dK2in(t)
dt
= K2p × S2(t− Td)× I2(t− Td)−K2in(t)×K2e (3.20)
dRBC(t)
dt
= K2in(t)−RBC(t)×K2out (3.21)
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where,
S2(t) = 1 +
S2max × Cdrug(t)
SC250 + Cdrug(t)
(3.22)
I2(t) = 1− ∆HGB(t)
IC250 + ∆HGB(t)
(3.23)
The parameters K2P , K2e, S2max, SC250, and IC250 are analogous to KP , Ke,
Smax, SC50, and IC50 used in Eq. 3.10–3.16. ConsideringK2out(0) = K2in(0)/RBC(0)
(derived from Eq. 3.21 at time 0) and assuming K2in(0) = Kin(0), we are able to
solve Eq. 3.10–3.12 along with Eq. 3.20–3.21. Finally, we could represent E(t) as
follows:
E(t) =
(K2in(t)−Kin(t) +RBCM(t)×Kout2 −RBC(t)×K2out)
RET (t)×Kout1 + 1 (3.24)
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Chapter 4: Evaluation of PK/PD Model Using Biological
Data
4.1 Agents
Epoetin-α was obtained from Ortho Biotech, Raritan, NJ. and darbepoetin-α (Aranesp,
Amgen, Inc. Thousand Oaks, CA) was purchased commercially. CNTO 530 is an
EPO-MimetibodyTM construct that contains two EMP-1 sequences as the pharma-
cophore. EMP-1 is a 20-amino acid peptide that was discovered by screening combi-
natorial libraries of random sequence peptides using phage display technology (John-
son et al., 1998). EMP-1 binds to EPO-R and expresses EPO-like bioactivity in
both in vitro and in vivo systems (Johnson et al., 1998; Livnah et al., 1998). EPO-
MimetibodyTM constructs were expressed in mammalian cells and purified by routine
methods and supplied by Centocor R&D as described previously (Bugelski et al.,
2008).
4.2 Rats
Female Sprague Dawley CD rats weighing approximately 300 grams were obtained
from Charles Rivers Laboratories (Raleigh, NC). Rats were housed 2 per cage in filter
topped plastic shoe-box style cages in a 12 hr light/dark cycle and fed and watered
ad libitum. The rats were identified with ear tags, placed at least 1 week prior to the
start of the study. Cage cards labeled with animal number, test article, treatment,
study number and Institutional Animal Care and Use Committee (IACUC) protocol
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number were affixed to the cages. All procedures were reviewed by the Centocor R&D
Institutional Animal Care and Use Committee and were conducted in an American
Association for Laboratory Animal Care (AALAC) approved facility.
4.3 Data Set
To study the pharmacodynamics of the drugs, rats (5-6/group) received a single s.c.
dose of the test articles. Epoetin-α was administered at doses of 0.003, 0.01, 0.03,
0.1 and 0.3 mg/kg. Darbepoetin-α was administered at doses of 0.001, 0.003, 0.01,
0.03, 0.1 and 0.3 mg/kg. CNTO 530 was administered at doses of 0.01, 0.03, 0.1, 0.3
and 1 mg/kg. Control rats received a 10 ml/kg s.c. dose of saline. Blood samples
were collected 3, 7, 14, 22, 29, 36, 43, 58 and 71 days after dosing from the retro-
orbital sinus under CO2 anesthesia and whole blood was analyzed with an Advia 120
hematology analyzer (Siemens, Terrytown, NY) as described previously (Kliwinski
et al., 2010). Data were collected from 3 separate experiments. The actual day of
blood collection was in some cases ± 1 day from that shown above. The actual day
of collection was used for modeling.
To study the pharmacokinetics of CNTO 530, rats were administrated a single
s.c. dose of 0.3 mg/kg and blood samples were collected via retro-orbital sinus at
0.3, 1 and 6 hrs and 1, 2, 3, 5, 9, 14, 20 and 27 days after dosing (4 rats per time
point) and plasma concentration measured as described previously (Martin et al.,
2010). PK values for epoetin-α and darbepoetin-α were obtained from the literature
(Woo et al., 2006; Yoshioka et al., 2007). Linear pharmacokinetics were assumed for
all three agents.
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4.4 Data Analysis
We fit the PK data to Eq. 3.1–3.3 and identified compartmental model parameters for
each drug. Then we performed non-compartmental analysis (NCA) on both the ob-
served data and the predicted data from the PK model using PKSolver (Zhang et al.,
2010). NCA is a set of statistical methods frequently used to study pharmacokinetics
of drugs. It assumes no model structure and uses simple calculations (DiPiro et al.,
2005). We then evaluated how well NCA agreed with results of the compartmental
PK model. Once we were satisfied with this analysis, the two-compartmental PK
model parameters were used to predict PK concentration versus time profile for other
dose levels. Using the principle of dose proportionality (Gabrielsson and Weiner,
2007; Gibaldi and Perrier, 1982), the concentration versus time profiles were then
used in our PD model.
In analyzing our PD data, we observed that drug responses at some low dosage
levels did not differ from control data. So we assumed that the drugs at dosage levels
did not induce biologically significant responses. Based on these observations, we used
RBC counts from the control rats to calculate a normal range with 95% confidence
interval (mean ± 1.96 standard deviation (SD)). If more than 95% of RBC counts
in rats with a certain dosage level fall into that range, we did not use that dosage
level for the drug in our analysis. As a result, we excluded epoetin-α at two lowest
dosage levels (0.003 mg/kg and 0.01 mg/kg), darbepoetin-α at the lowest dosage
levels (0.001 mg/kg) and CNTO 530 at two lowest dosage levels (0.01 mg/kg and
0.03 mg/kg). This gave us a data set of 78 rats. We applied our PD model to the
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merged dataset. The time points of RET and RBC for all dose levels of each drug
were analyzed simultaneously with predicted PK profiles. The expected HGB levels
were calculated using Eq. 3.16.
Both PK and PD model fittings were done by maximum likelihood (ML) method,
which is available as a computation option in the ADAPT II software package (D’Argenio
and Schumitzky, 1997). The basic idea of ML is to select parameter values to max-
imize a preset maximum likelihood function (Le Cam, 1990). Since this software
requires a variance model, we incorporated the following relationship:
Vi = (σinter + σslope × Yi)2 (4.1)
where Vi is the variance at the ith data point, σinter and σslope are the variance model
parameters, and Yi represents the model predicted value at the ith time point. For
example, we assume that σinter = 0.2 and σslope = 0.1 in Eq. 4.1. Then the variance
model represents an error process with a standard deviation of 0.2 plus 10% of the
measured quantity.
4.5 Results
4.5.1 PK model results
The concentration values at each time point of three drugs are shown in Figures 4.1–
4.3. We fit the mean values of the concentration data for each drug to our model
using the bioavailability, F, values of 0.59 for epoetin-α (Woo et al., 2006), 0.54 for
darbepoetin-α (Yoshioka et al., 2007), and 0.75 for CNTO 530 from our experiments.
37
The predicted concentration versus time profiles are shown in Figures 4.1–4.3 as solid
lines. To evaluate the PK model, we calculated non-compartmental parameters from
model predictions and compared them with those calculated from experimental data.
As shown in Table 4.1, the results from the PK model are within or close to mean ±
SD of the results of NCA from experimental data. This indicates that our PK model
is a good prediction of concentration versus time profiles.
Figure 4.1: Epoetin-α concentration versus time profile (0.0405 mg/kg) esti-
mated from experimental data provided by Woo et al. (2006).
38
Figure 4.2: Darbepoetin-α concentration versus time profile (0.0005 mg/kg)
estimated from experimental data provided by Yoshioka et al. (2007).
Figure 4.3: CNTO 530 concentration versus time profile (0.3 mg/kg) estimated
from our PK experiment.
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Table 4.1: Non-compartmental analysis for epoetin-α, darbepoetin-α and
CNTO 530.
Parameters Definition Epoetin-α Darbepoetin-α CNTO 530
(0.0405 mg/kg) (0.0005 mg/kg) (0.3 mg/kg)
From
dataa
From
pre-
dic-
tionb
From
datac
From
pre-
dic-
tionb
From
dataa
From
pre-
dic-
tionb
AUC0−inf Area under the
curve
1920.00
2064.66
74.12
70.01
350249
336367
(ng.h/ml) ± 118.40 ± 5.6 ± 33957
Cmax Maximal
concentration
83.68
66.94
1.36
1.21
2062
1843
(ng/ml) ± 18.34 ± 0.99 ± 164
Tmax Time that
Cmax occurs
12.2
11.27
15
21.82
54.86
58.91
(h) ± 1.72 ± 6 ± 17.18
T1/2 Terminal half
life
7.76
9.73
15.09
17.92
72.47
70.34
(h) ± 0.9 ± 0.48 ± 5.42
CL/F Apparent total
clearance
21.16
19.62
6.8
7.18
0.86
0.89
(ml/h/kg) ± 1.29 ± 0.5 ± 0.08
ais expressed as mean ± SD that were calculated from 2000 simulation based on data time points
bis expressed as values that were calculated from predicted curves of PK model
cis taken from literature (Yoshioka et al., 2007)
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We plotted predicted concentration profiles for all three drugs at a dosage level
of 0.3 mg/kg (Figure 4.4). The plot suggests that at the same dosage, epoetin-α
concentration profile has the lowest peak and shortest active time; CNTO 530 has
the highest peak and longest active time.
Figure 4.4: Predicted concentration of all three ESAs at a dosage level of 0.3
mg/kg.
The estimated PK model parameters were listed in Table 4.2. In our study, we
found that the estimated elimination rates (Kel), volume of distribution (VC) and
absorbtion rate (Ka) are highest for epoetin-α, and lowest for CNTO 530. The
relatively slow rate of decrease of CNTO 530 concentration shown in Figure 4.3 is
likely due to the fact that CNTO 530 has lower absorption and elimination rates than
the other two ESAs. The estimated values for inter-compartmental rate (KCP ) are
close to 0 for epoetin-α and darbepoetin-α. This implies that one compartmental PK
model might also work for these two drugs. However, KCP for CNTO 530 is 0.01
h−1, which implies that two-compartmental PK model should work better for CNTO
530. This reinforces our choice of using a two-compartmental PK model for all three
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drugs.
Table 4.2: Estimated PK parameters for all three ESAs using our model.
Parameters Definition Epoetin-α Darbepoe-
tin-α
CNTO
530
Kel (h
−1) Elimination rate 0.11 0.05 0.01
Vc (ml/kg) Volume of distribution
of central compart-
ment
142.6 82.33 67.28
Ka (h
−1) Absorption rate 0.11 0.05 0.03
KCP (h
−1) Inter-compartment
rate from central to
peripheral
∼0.00 ∼0.00 0.01
KPC (h
−1) Inter-compartment
rate from peripheral to
central
0.61 1.93 0.87
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4.5.2 PD model results
Our experimental data time span is up to 72 days (1728 hours). Other studies in the
literature did not exceed 60 days (Agoram et al., 2006; Loeﬄer et al., 1989; Ramakr-
ishnan et al., 2004; Wichmann et al., 1989; Woo et al., 2006; Wulff et al., 1989) and
thus their models have difficulty fitting our data. For example, when we implemented
Woo et al.’s model, we found that RET counts were suddenly increased and RBC
counts suddenly dropped after 1440 hours (see Figure 4.5), which is inconsistent with
actual responses. Hence, we designed our PD model to incorporate a longer time
span.
Figure 4.5: We implemented the PK/PD model in Woo et al. (2006) at a dose
1350 IU/kg (0.0135 mg/kg) and ran an extended simulation that went to 1728
hours (72 days). A significant inconsistency in the model can be seen in the plots
of RET and RBC after 1440 hours (60 days).
The plots of the measured data and the predicted curves from our PD model for
the three ESAs are shown in Figures 4.6–4.8. The RET, RBC and HGB profiles for
all three drugs share the same characteristics. Each profile quickly increases a short
time after dosing, then decreases to below the baseline and eventually recovers back
to the initial level. These results suggest that our PD model fits the response data
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of all three ESAs with reasonable accuracy and allows us to study drug effects over a
longer time span (up to 72 days) than previous models.
Figure 4.6: The plots of the experimental data (RET, RBC and HGB) and their
model predicted curves from our PD model for epoetin-α.
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Figure 4.7: The plots of the experimental data (RET, RBC and HGB) and their
model predicted curves from our PD model for darbepoetin-α.
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Figure 4.8: The plots of the experimental data (RET, RBC and HGB) and their
model predicted curves from our PD model for CNTO 530.
The goodness-of-fit plots of our PD model are shown in Figures 4.9–4.11. For
darbepoetin-α and CNTO 530, the observed versus predicted values for RET, RBC
and HGB fell along the line of unity, indicating that the PD model describes the data
reasonably well. For epoetin-α, the goodness-of-fit plots for RET, RBC and HGB
have some points much lower than the line of unity. This suggests that epoetin-α
data have a large variance (see Figure 4.6) and thus the PD model parameters also
have a large variance.
The estimated parameters for our PD model are listed in Table 4.3. To en-
able direct comparison of the parameters, we normalized each PD model parameter
by dividing it by the mean value over all three ESAs and plotted them in Figure
4.12 (Krzyzanski et al., 2005). We see that TRET (lifespan of reticulocytes), Smax
(maximum stimulatory effect), 1/Ke (time to change Kin(t)), and IC50 (potency of
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Figure 4.9: Goodness-of-fit of RET, RBC and HGB for PD modeling of epoetin-
α.
Figure 4.10: Goodness-of-fit of RET, RBC and HGB for PD modeling of
darbepoetin-α.
Figure 4.11: Goodness-of-fit of RET, RBC and HGB for PD modeling of CNTO
530.
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inhibitory effect) are statistically similar for all three ESAs. The mean value of Td
(time to mobilize reticulocytes and RBCs) for epoetin-α (50.14 h) and darbepoetin-α
(46.24 h) are similar, but higher than the other two ESAs. Also, the potency value
(SC50) for CNTO 530 is significantly different than it is for epoetin-α or darbepoetin-
α (see Figure 4.12) suggesting that a larger CNTO 530 concentration is required to
reach the same stimulation effect for RBCs than for epoetin-α or darbepoetin-α.
Table 4.3: Estimated PD parameters for all three ESAs using our model.
Parameters aEpoetin-α bDarbepoetin-α cCNTO 530
Mean dCV(%) Mean CV(%) Mean CV(%)
TRET 31.70 269 25.08 38 44.16 28
Td (h) 50.14 32 46.24 7 18.65 39
1/Ke (h) 49.20 134 47.12 17 78.64 32
Smax 13.27 82 15.42 10 12.04 21
SC50 (ng/ml) 7.39 241 12.31 20 710.4 33
IC50 (g/dl) 0.97 135 0.97 18 1.32 32
Note:
a: used doses of 0.03 mg/kg, 0.1 mg/kg, and 0.3 mg/kg
b: used doses of 0.003 mg/kg, 0.01 mg/kg, 0.03 mg/kg, 0.1 mg/kg, and 0.3 mg/kg
c: used doses of 0.1 mg/kg, 0.3 mg/kg, and 1 mg/kg
d: stands for coefficient of variation expressed as SD/mean
Figure 4.13 shows E(t), the combined stimulation/inhibition effect, for the three
drugs all at the same dosage of 0.1 mg/kg. We observed that the curves of E(t)
decreased quickly a short time after dosing, then increased above the baseline and
returned gradually to the baseline. The plots suggest that there is a combination of
stimulation and inhibition which affects the conversion of reticulocytes into mature
RBCs.
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Figure 4.12: Means and SDs of the normalized estimates of the PD parameters
for all three ESAs.
Figure 4.13: E(t) for all three ESAs with dosage 0.1 mg/kg.
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4.6 Discussion
Typical PK/PD models from the literature (Ette and Williams, 2007; Ramakrish-
nan et al., 2003; Woo and Jusko, 2007) use compartmental structures where various
pools represent ESA concentrations or cell populations at different stages or con-
ditions. In PK modeling, both one-compartmental and two-compartmental models
have been used (Krzyzanski and Jusko, 1998; McLennan et al., 2006). They can be
mathematically expressed using linear differential equations (Agoram et al., 2006) or
non-linear differential equations (Woo and Jusko, 2007). In PD modeling, indirect
response models and cell lifespan models were developed to analyze the dynamics of
erythropoietic responses, such as reticulocyte (RET) counts, red blood cell (RBC)
counts, and hemoglobin (HGB) levels. In 1993, Dayneka et al. proposed four basic
models for characterizing indirect PD responses with differential equations and Hill
functions, which have been widely used in studying the pharmacodynamics of ESAs.
Krzyzanski et al. (2005) developed a PK/PD model for epoetin-α after multiple s.c.
doses in healthy human populations, where catenary cell production and cell lifes-
pan concepts (Krzyzanski et al., 1999) were used to fit the RET percentages, RBC
counts and HGB levels. Their PD model combined first-order loss rates and life span
delayed loss rates. However, they did not include inhibitory effects in their model.
Woo et al. (2006) developed a PK/PD model for epoetin-α in rats where they incor-
porated cell lifespan loss concept and indirect response to ESAs. Unlike Krzyzanski,
Woo’s model included an inhibition feedback from hemoglobin. The lifespan of RBC
in their PD model was assumed to be 60 days (1440 hours) and their experimental
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data were collected within 24 days (576 hours) of epoetin-α administration. When
we attempted to implement their model for data collected more than 60 days after
epoetin-α administration, we found that these data are not well modeled due to the
cell lifespan loss concept in the model. This concept introduces a significant decline
of RBC counts after 60 days, which is not biologically reasonable. Hence, the lifespan
loss concept was inappropriate for modeling long-term erythropoietic responses, such
as the RBC count after 60 days. Similarly, Agoram et al. (2006) developed a PK/PD
model of darbepoetin-α in humans. When we implemented this model and tested
it with our data, we found that this PD model could not capture the “below the
baseline” phenomenon in hemoglobin data observed after 60 days.
Pharmacokinetic models of ESAs have also been extensively studied in the liter-
ature (Agoram et al., 2006; Ette and Williams, 2007; Khorasheh et al., 1999). After
testing various model structures we found that a simple linear two-compartmental
PK model is applicable to all three drugs in our study. We developed a new indirect
response PD model, which included negative feedbacks and effectively described drug
response data of all three drugs in our study. We used a variable to model the pro-
duction rate change of RET and introduced a joint regulatory effect E(t) controlled
by the drug concentration and HGB level, which regulates how RETs become mature
RBCs. The variable production rate helps to better model drug effects in the ini-
tial stages after administration. The feedback mechanism provided by I(t) and E(t)
caused the response curve to decrease below baseline and then gradually return to
the normal levels mimicking experimental results.
Our PD model fit the experimental data and showed similar trends in the time
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profiles for RET counts, RBC counts and HGB levels for all three drugs. RET counts
increased shortly after dosing, reached a peak, and then decreased. This decrease in
RET counts continued below baseline values and then gradually returned back to the
baseline. This observation was also reported in the literature (Ramakrishnan et al.,
2004; Woo et al., 2006). For RBC and HGB, the trends are similar. For epoetin-α,
unlike for darbepoetin-α and CNTO 530, the RBC count does not change significantly
after administration even at a high dose level.
The development of a single PK/PD model for all three drugs allows parameter
comparisons between ESAs to be easily made. It is shown in Table 4.2 and 4.3 that
the PK/PD parameters of epoetin-α and darbepoetin-α are more similar to each other
than they are to CNTO 530. Compared to epoetin-α and darbepoetin-α, CNTO 530
provides the advantage of longer half life (t1/2) and shorter mobilization time (Td),
which indicates that it mobilizes reticulocytes and RBCs faster and the stimulatory
effect lasts longer. However, CNTO 530 has a much larger SC50 (less potency),
which means it requires a larger drug concentration to reach the same stimulation
effect for RBCs provided by either epoetin-α or darbepoetin-α. From Figure 4.8, it is
clear that CNTO 530 has the highest peak and stays above the baseline the longest.
This suggests that for CNTO 530 the stimulation of RBC generation gives it a clear
advantage over epoetin-α and darbepoetin-α despite relatively less potency (SC50).
4.7 Conclusion
We developed a single PK/PD model for three ESAs. The PK model is an existing
linear two-compartmental model (DiPiro et al., 2005). The new PD model is an
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indirect response model that includes several negative feedbacks and fits response
data for up to 72 days. When comparing among the erythropoietic responses to
doses that increased RBC, the coefficients of the model indicate that despite having
a lower potency, CNTO 530 caused a more rapid mobilization of RET. The results of
the PK/PD modeling suggest that CNTO 530 stimulates erythropoiesis in a similar
fashion to epoetin-α and darbepoetin-α and that the PK properties of an ESA are
the most important factor in determining efficacy.
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Chapter 5: An Application of PK/PD modeling: Dose
Threshold Study
5.1 Introduction
Pharmaceutical compounds are known to have a dose threshold below which they do
not have a “significant” effect on a specific biological process (Eaton and Kalaassen,
1996). The determination of what is “significant” and which specific biological process
is to be targeted affects the value of the dose threshold. For instance, in the treatment
of anemia the biological process of interest is erythropoiesis and a drug with dose
exceeding a certain threshold has a “significant” effect if it causes a noticeable increase
in red blood cell counts above baseline. The key benefit of knowing the dose threshold
is that a dose which is slightly above the dose threshold (minimum effective dose) can
be administered. By prescribing an appropriate dosage, side effects of the compound
may be diminished and costs of treatment may be reduced.
In many cases the effectiveness of a pharmaceutical compound is determined by
non-quantitative analysis of experimental data (Braga et al., 1999; Reigner et al.,
2003; Sathyanarayana et al., 2009). This type of subjective analysis is prone to errors
in estimating the drug threshold due to differences in opinion between professionals.
We suggest two approaches to improve this situation. One is based on the assump-
tion that when a dose is below threshold the pharmacodynamic response is constant
(within some “small” distance from baseline). Conversely when a dose is above thresh-
old the pharmacodynamic response has a “significant” number of readings which are
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not within a “small” distance from baseline. The second approach assumes a good
PK/PD model. The experimental drug responses at doses above the threshold should
agree with the model prediction much better than at doses below the threshold.
In the first approach, we calculate a normal range with a certain confidence interval
using data from control subjects. Then we determine how many drug response data
points fall in the range. If the number is large, the response profile does not differ
from control; thus the corresponding dosage is below the threshold. Otherwise, the
dosage is above threshold.
In the second approach, we used our existing PK/PD model to predict drug re-
sponses at each dosage and applied R2, coefficient of determination, to measure how
well the prediction agrees with experimental data. If R2 is significantly small, we say
the corresponding dose is below threshold and if R2 is large, we say the dose is above
threshold.
5.2 Experimental Data and Data Analysis
The hematology data used in the dose threshold study consisted of blood samples
from sixty three rats. The rats were evenly subdivided into nine groups. One of the
groups was a control group while the other eight groups were each subcutaneously
administered with a different dose of CNTO530. The dosage levels used for each
of the eight groups were 0.005 mg/kg, 0.01 mg/kg, 0.02 mg/kg, 0.04 mg/kg, 0.08
mg/kg, 0.16 mg/kg, 0.32 mg/kg, and 1 mg/kg. For each group blood samples were
drawn from all rats at day 3, 9, 16, 23, 30, 37, 57, and 72 after administration. For
each blood sample reticulocyte count (RET), red blood cell count (RBC), and the
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hemoglobin level (HGB) were obtained using an Advia 120 hematology analyzer.
5.3 Two Criteria
The following method was used to find the dosage levels at which the drug response
data were not significant from the control data. All RBC counts from the control
rats were used to calculate a normal range with 95% confidence interval (mean ±1.96
SD). If more than 95% of RBC counts of the drug at a specific dosage level fell into
that range, we considered the dosage level below the threshold, i.e. the drug response
profile is flat and the drug fails to cause a statistically noticeable change. Conversely,
if less than 95% of RBC counts at a specific dosage level fall into that range, we
considered the dosage level above the threshold.
For the second approach to determine dose threshold, we applied our PK/PD
model to the experimental CNTO 530 dataset and assessed the model fit using R2,
the coefficient of determination used to quantify goodness of fit. Its definition is as
follows:
R2 = 1− SSE/SST (5.1)
where SSE is sum of square of errors between observations and predicted points and
SST is sum of square of errors from observations to the mean of observations (a
horizontal line). A higher value of R2 indicates that the model fits the data better.
When R2=1.0, all points lie exactly on the curve with no scatter. When R2 = 0.0, the
best-fit curve fits the data no better than a horizontal line going through the mean
of all Y values. R2 can be negative, if the best-fit curve fits the data even worse than
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does a horizontal line.
5.4 Results
We analyzed drug response data at eight dosage levels using the 95% criterion. The
four lowest dosage levels (0.005 mg/kg, 0.01 mg/kg, 0.02 mg/kg, and 0.04 mg/kg)
were found to be below the threshold. The remaining four dosage levels (0.08 mg/kg,
0.16 mg/kg, 0.32 mg/kg and 1 mg/kg) were found to be above the threshold and able
to induce detectable drug response.
We calculated the percentage of RBC counts within the normal range for each of
eight dosages and show them in Table 5.1. For each drug, there are 7 rats and each
rat was sampled at 8 different time points. So there are maximum 56 time points.
However, there are fewer usable time points for some dosages because some samples
were clotted or some rats were sacrificed before the end of our study.
Table 5.1: Percentage of RBC counts within the normal range of CNTO 530.
Dosage level of
CNTO 530
Number of RBC
counts within the
normal range
Total Usable Time
Points
% of RBC counts
within the normal
range
0.005 mg/kg 54 54 100
0.01 mg/kg 54 54 100
0.02 mg/kg 53 54 98
0.04 mg/kg 53 54 98
0.08 mg/kg 46 56 82
0.16 mg/kg 35 55 64
0.32 mg/kg 19 56 34
1 mg/kg 13 55 24
We then applied our PD model to predict drug response data. The model fitting
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plots for RET, RBC and HGB at the eight dosage levels of CNTO 530 are shown in
Figure 5.1–5.3. These plots share the same characteristics. For each plot, we see a
quick increases in the variable after a short delay, then a decrease to below baseline,
and a slow recover to the initial level. This trend was also reported in previous PK/PD
studies (Ramakrishnan et al., 2004; Woo et al., 2006). From these figures, it is clear
that our PD model fit the data well for the highest four dosage levels. Additionally,
for the highest four dosage levels, the model predictions and observed data for RETs,
RBCs and HGBs fell along the line of unity (See Figure 5.4), which indicates that
the model fit the drug response data well at 0.08, 0.16, 0.32 and 1 mg/kg.
The coefficients of determination R2 are shown both in Figures 5.1–5.3 and in
Table 5.2. For the lowest four dosage levels, R2 values for RET, RBC and HGB are
either relatively small (< 0.1) or negative except for RET at 0.04 mg/kg. When R2
for RET prediction is about 0.5 but negative for both RBC and HGB. This may
indicate that this dosage is close to the threshold, showing mixed model prediction
results. For the highest four dosage levels, R2 values for RET, RBC and HGB are
quite large, indicating that our PD model describes the data reasonably well. In
summary, by measurement of R2, we were able to verify our finding of dose threshold
with the normal range method. This confirms that the dose threshold is between 0.04
mg/kg and 0.08 mg/kg and is consistent with our previous analysis, which suggested
the dose threshold should be between 0.03 and 0.1 mg/kg (see Chapter 4).
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Figure 5.1: RET profiles after s.c. administration of CNTO 530 with dosage
levels of 0.005 mg/kg, 0.01 mg/kg, 0.02 mg/kg, 0.04 mg/kg, 0.08 mg/kg, 0.16
mg/kg, 0.32 mg/kg, and 1 mg/kg.
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Figure 5.2: RBC profiles after s.c. administration of CNTO 530 with dosage
levels of 0.005 mg/kg, 0.01 mg/kg, 0.02 mg/kg, 0.04 mg/kg, 0.08 mg/kg, 0.16
mg/kg, 0.32 mg/kg, and 1 mg/kg.
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Figure 5.3: HGB profiles after s.c. administration of CNTO 530 with dosage
levels of 0.005 mg/kg, 0.01 mg/kg, 0.02 mg/kg, 0.04 mg/kg, 0.08 mg/kg, 0.16
mg/kg, 0.32 mg/kg, and 1 mg/kg.
Figure 5.4: Goodness-of-fit of RET, RBC and HGB for PD model predication
of CNTO 530 at 0.08, 0.16, 0.32 and 1 mg/kg.
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Table 5.2: R2 calculated from the prediction of drug responses (RET, RBC and
HGB) using our model for CNTO 530
Dosage level of CNTO
530
RET RBC HGB
0.005 mg/kg -0.3837 -0.1897 -0.2486
0.01 mg/kg 0.0335 -0.5543 -0.3993
0.02 mg/kg 0.0793 -0.5811 -1.2390
0.04 mg/kg 0.5110 -0.4567 -0.3479
0.08 mg/kg 0.8582 0.3852 0.4346
0.16 mg/kg 0.9087 0.7371 0.7133
0.32 mg/kg 0.9278 0.6581 0.7136
1 mg/kg 0.7509 0.4489 0.4987
5.5 Discussion
The identification of drug effect threshold depends on the type of response that is mea-
sured and can vary among individuals. Even so, it is important to know the dosages
at which there is no detectable drug effect and to determine thresholds on minimum
effective dose. Using the minimum effective dose can help reduce the amount and
consequently the toxicity and cost of the therapy (Braga et al., 1999).
Based on our analysis in this chapter and our development of the PK/PD model,
we showed that the dosage threshold for single dose administration of CNTO 530
in rats is between 0.04 mg/kg and 0.08 mg/kg. These methods can help scientists
to find dosage threshold for other pharmaceutical compounds during the process of
drug development and for physicians to prescribe appropriate doses of medications
for patients.
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Chapter 6: Summary and Future Work
6.1 Summary of Thesis
In this thesis, we developed a single PK/PD model for three ESAs: epoetin-α,
darbepoetin-α and CNTO 530. We found that a classical two-compartmental PK
model from the literature (DiPiro et al., 2005) can be applied to our data. How-
ever, it was discovered that the available PD models were not able to adequately
describe our data. So we developed a new indirect response model. Instead of using
a constant as in previous studies, we used a variable to model the production rate of
RET and introduced a joint regulatory effect E(t) which is controlled by both drug
concentration and change in hemoglobin level. This joint effect E(t) regulates how
RET become mature RBC. Applying our PK/PD model to the experimental data
of the three drugs, we obtained their model parameters, which make a meaningful
comparison possible. After carefully comparing the parameters, we found that the
drug action of CNTO 530 is significantly different from the other two drugs.
Next, we developed two statistical criteria to identify dose threshold of a drug.
For the first criterion, by computing how many data points in a drug experiment are
in the 95% confidence interval of control data, we can determine minimum effective
drug doses. For the second one, we used R2 to measure and compare the fitting of
PK/PD models under different doses and determine effective doses. When we applied
our methods to the CNTO 530 data set, we got very similar results, suggesting their
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validity.
6.2 Future Work
• Test our PK/PD model with more dosage data
Our PK/PD model was fitted and tested with data from three ESAs, epoetin-
α, darbepoetin-α and CNTO 530 over a dose range of 0.001 mg/kg to 1mg/kg.
The model can be tested at higher dose levels to determine its validity over a
much wider range of treatments.
• Improve PD model
A more accurate PD model may be developed by expanding the “Early Stages”
compartment in our model. This could include data on BFU-E, CFU-E, Pro-
EB, Baso-EB, Poly-EB and Ortho-EB. Although this will complicate our model
we will have a more precise picture of RBCM production.
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Appendix A: List of Symbols
AUC Area under the concentration vs. time curve
Cdrug(t) Concentration of drug in the central compartment at time t
CL Clearance: the volume of plasma cleared of the drug per unit time
CL/F Apparent clearance
Cmax Maximum concentration
CP (t) Concentration of drug in the peripheral compartment at time t
C(t) Concentration of drug in the plasma at time t
EC50 The drug concentration that produces half of the maximum effect
Ef(t) The variable of pharmacological effect
Emax The maximum achievable effect
E(t) Effect function between RET and RBCM, E(t)=E1(t)+E2(t)
E1(t) Effect function from drug concentration
E2(t) Effect function from change of hemoglobin level
F Bioavailability: the fraction of drug that is absorbed
HGB(t) Hemoglobin levels at time t
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IC50 HGB change for producing 50% maximum inhibition
IIC50 The drug concentration which produces half of maximum inhibitory effect
II(t) Inhibitory function of response
Input(t) Concentration of drug at the s.c. injection site at time t
Imax Maximum inhibition of responses by HGB change.
Ka Absorption rate
KCP Inter-compartment exchange rate from central compartment to
peripheral compartment
Ke Output rate constant for Kin(t)
Kel Elimination rate
Kin The zero-order constant for production of the response
Kin(t) Production rate variable for reticulocytes
Km The plasma drug concentration at which the elimination rate reaches
50% Vmax in Michaelis-Menton kinetics
Kout First-order rate constant for loss of the response
Kout1 First-order elimination rate of reticulocyte.
Kout2 First-order elimination rate of RBC
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KPC Inter-compartment exchange rate from peripheral compartment to
central compartment
n The shape factor in the sigmoid Emax model
RBC(t) Red blood cell counts at time t
RET (t) Reticulocyte counts at time t
R(t) The variable for response to a drug
R2 Coefficient of Determinant
Td Delayed time for stimulatory effect and inhibitory effect
TRET Life span of reticulocyte
SC50 The drug concentration required for producing 50maximum stimulation
of Kin(t)
SSC50 The drug concentration for producing 50% maximum stimulation of
response
Smax Maximum stimulation of Kin(t) by a drug
SSmax Maximum stimulation of responses by a drug
SS(t) Stimulatory function of response
Tmax the time when Cmax occurs
TR Average cell life span
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t1/2 Elimination half-life
VC Volume of distribution at the central compartment
Vd volume of distribution
Vi the variance at the ith data point
Vmax The maximum elimination rate in Michaelis-Menton kinetics
Yi The model predicted value at the ith time point.
λz terminal elimination rate const
σinter A parameter of variance model
σslope A parameter of variance model
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Appendix B: List of Abbreviations
AALAC American Association for Laboratory Animal Care
AIDS Acquired immune deficiency syndrome
Baso-EB Basophilic-erythroblast
BFU-E Burst forming unit-erythroid
CFU-E Colony forming unit-erythroid
CV Coefficient of variation expressed as SD/mean
EPO Erythropoietin
EPO-R Erythropoietin Receptor
ESA Erythropoiesis Stimulating Agent
EMP1 Erythropoietin mimetic peptide-1
HGB Hemoglobin
HSC Hematopoietic stem cell
IACUC Institutional Animal Care and Use Committee
i.m. Intramuscular
i.v. Intravenous
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MCH Mean corpuscular hemoglobin
ML Maximum Likelihood
NCA Non-compartmental analysis
Ortho-EB Orthochromic-erythroblast
PD Pharmacodynamics
PK Pharmacokinetics
PK/PD Pharmacokinetic/Pharmacodynamic
Poly-EB Polychromatophilic-erythroblast
Pro-EB Proerythroblast
RBC Red blood cell
RBCM Mature red blood cell
RET Reticulocyte
rHuEPO Recombinant human erythropoietin
s.c. Subcutaneous
SD Standard Deviation
SSE Sum of square of errors between observations and predicted points
SST Sum of square of errors from observations to the mean of observations (a
horizontal line)
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